Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III multicenter study in epithelial ovarian carcinoma FIGO stage IIb-IV comparing treatment with paclitaxel and carboplatin to paclitaxel and carboplatin sequentially followed by topotecan

Next Previous
X
Search
Trial Profile

Phase III multicenter study in epithelial ovarian carcinoma FIGO stage IIb-IV comparing treatment with paclitaxel and carboplatin to paclitaxel and carboplatin sequentially followed by topotecan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topotecan (Primary) ; Carboplatin; Paclitaxel
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Sep 2020 Results assess the role of KELIM regarding the probability of long progression-free survivorship (PS) > 5 years after 1st line treatment (AGO-OVAR 9; AGO-OVAR 7 and ICON 7) presented at the 45th European Society for Medical Oncology Congress
    • 01 Apr 2019 Results validating the higher predictive & prognostic values of KELIM during first line treatments in ovarian cancer patients published in the Clinical Cancer Research
    • 06 Jun 2017 Results (n=4578) of validation of prognostic value of KELIM regarding PFS and OS in phase 3 trial (AGO-OVAR 9, AGO-OVAR 7, ICON 7) datasets presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top